Abstract
Several inflammatory mediators regulate the evolution of atherosclerosis. C-reactive protein (CRP) is an acutephase reactant, with a direct effect in inflammatory processes characterizing atherosclerosis. For this reason, CRP is actually considered as a factor, rather than simply a cardiovascular risk marker. The recent demonstration of CRP production not only by the liver, but also within atherosclerotic plaques by activated vascular cells, suggests a possible dual role, as both systemic and tissue molecule. Although more studies are needed, some therapeutic approaches to reduce CRP levels have been performed with encouraging results. Behavioral or pharmacologic interventions have been shown to reduce both CRP levels and the associated risk of cardiovascular acute events. Therefore, although most of national Cardiovascular Associations do not suggest high sensitivity CRP screening of the entire adult population as a public-health measure to stratify the cardiovascular risk, serum hs-CRP levels could be a promising target for therapies focused on reducing cardiovascular risk.
Keywords: cardiovascular risk, statins, C-reactive protein, Atherosclerosis
Current Chemical Biology
Title: Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
Volume: 3 Issue: 1
Author(s): Francois Mach and Fabrizio Montecucco
Affiliation:
Keywords: cardiovascular risk, statins, C-reactive protein, Atherosclerosis
Abstract: Several inflammatory mediators regulate the evolution of atherosclerosis. C-reactive protein (CRP) is an acutephase reactant, with a direct effect in inflammatory processes characterizing atherosclerosis. For this reason, CRP is actually considered as a factor, rather than simply a cardiovascular risk marker. The recent demonstration of CRP production not only by the liver, but also within atherosclerotic plaques by activated vascular cells, suggests a possible dual role, as both systemic and tissue molecule. Although more studies are needed, some therapeutic approaches to reduce CRP levels have been performed with encouraging results. Behavioral or pharmacologic interventions have been shown to reduce both CRP levels and the associated risk of cardiovascular acute events. Therefore, although most of national Cardiovascular Associations do not suggest high sensitivity CRP screening of the entire adult population as a public-health measure to stratify the cardiovascular risk, serum hs-CRP levels could be a promising target for therapies focused on reducing cardiovascular risk.
Export Options
About this article
Cite this article as:
Mach Francois and Montecucco Fabrizio, Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk, Current Chemical Biology 2009; 3 (1) . https://dx.doi.org/10.2174/2212796810903010060
DOI https://dx.doi.org/10.2174/2212796810903010060 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis of New 1-Substituted-1H-1,2,3,4-Tetrazoles from L-α-Amino Acids and Their Biological Assays
Letters in Organic Chemistry Evaluation of in-vitro Anti Diabetic Activity of a Siddha Herbo- Mineral Drug
Current Traditional Medicine Development and Optimization of Self-emulsifying Drug Delivery Systems (SEDDS) for Enhanced Dissolution and Permeability of Rosuvastatin
Current Drug Delivery The Epidemiology of Adiposity and Dementia
Current Alzheimer Research MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters The Role of Statins in Oxidative Stress and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment
Current Alzheimer Research EDITORIAL [Hot Topic: Biomarkers in Cardiovascular Disease (Guest Editor: Dimitris Tousoulis)]
Current Medicinal Chemistry Knowledge and Perceptions Towards Cardiovascular Disease Prevention Among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations
Current Diabetes Reviews Synthesis and Evaluation of Compounds Containing 4-arylpiperazinyl Moieties Linked to a 2-(pyridin-3-yl)-1H-benzimidazole as p38 MAP Kinase Inhibitors
Letters in Drug Design & Discovery Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Preface
Current Nutrition & Food Science Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Dynamics of Telomere Length in Different Age Groups in a Latvian Population
Current Aging Science The Role of Psychiatrist in Organ Transplantation: From Gate-keeper to Patient's Advocate
Current Psychiatry Reviews